TheEdgeResearch
Home / Stocks / SHJBF

Shanghai Junshi Biosciences Co., Ltd. (SHJBF)

OTC Healthcare Biotechnology
$3.35 ▲ +0.00%
Market Cap
$4.84B
Sector
Healthcare
Industry
Biotechnology
Beta
0.58
52-Wk Range
2.99-4.23
CEO
Cong Li
Country
CN
Currency
USD

Shanghai Junshi Biosciences Co., Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $3.35, up 0.00% on the session, giving a market capitalisation of $4.84B. On trailing twelve-month figures it carries a trailing P/E of -60.03, a net margin of -13.4%. Its beta of 0.58 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-60.03
Price / Sales
6.00
Price / Book
4.42
EV / EBITDA
-72.94
Gross margin
79.4%
Operating margin
-16.0%
Net margin
-13.4%
Return on equity
—
Debt / equity
1.17
Current ratio
2.05
Dividend yield
0.0%
Payout ratio
-12.1%
Company profile
Exchange
Other OTC
Employees
2,903
IPO date
2021-02-02
Headquarters
Shanghai, SH, CN
About Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.

More research on SHJBF
SHJBF technical analysis SHJBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →